InProTher pitch at Novo BII demo-day by Peter J. Holst
InProTher treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where InProTher is presented by Associate Professor Peter Johannes Holst.
Steven Glazer joins Inprother as Medical Advisor
Steven Glazer has many years of international experience in healthcare and biotechnology. He has held a number of senior positions within pharmaceutical and bioengineering companies in Europe and the US, including Novo Nordisk, Zealand Pharma,…
InProTher presentation by Peter J. Holst
InProTher treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where InProTher is presented by Associate Professor Peter Johannes Holst.
Inprother research published in Oncotarget
We are very happy to announce that a new scientic article by the Inprother-team has been accepted in the Oncotarget journal. The article: “Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in…
Inprother got investment by Novo Nordisk Foundation
InProTher is one of the three companies to join the BII Creation House program run by Novo Nordisk Foundation. After a successful Business Acceleration Academy, InProTher was recommended for the program by an external committee…